1. Home
  2. PRAX vs BVS Comparison

PRAX vs BVS Comparison

Compare PRAX & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • BVS
  • Stock Information
  • Founded
  • PRAX 2015
  • BVS 2011
  • Country
  • PRAX United States
  • BVS United States
  • Employees
  • PRAX N/A
  • BVS N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • PRAX Health Care
  • BVS Health Care
  • Exchange
  • PRAX Nasdaq
  • BVS Nasdaq
  • Market Cap
  • PRAX 599.7M
  • BVS 656.9M
  • IPO Year
  • PRAX 2020
  • BVS 2021
  • Fundamental
  • Price
  • PRAX $33.79
  • BVS $7.82
  • Analyst Decision
  • PRAX Strong Buy
  • BVS Strong Buy
  • Analyst Count
  • PRAX 9
  • BVS 4
  • Target Price
  • PRAX $123.33
  • BVS $15.00
  • AVG Volume (30 Days)
  • PRAX 570.3K
  • BVS 339.2K
  • Earning Date
  • PRAX 05-12-2025
  • BVS 05-06-2025
  • Dividend Yield
  • PRAX N/A
  • BVS N/A
  • EPS Growth
  • PRAX N/A
  • BVS N/A
  • EPS
  • PRAX N/A
  • BVS N/A
  • Revenue
  • PRAX $8,553,000.00
  • BVS $573,280,000.00
  • Revenue This Year
  • PRAX N/A
  • BVS N/A
  • Revenue Next Year
  • PRAX $789.73
  • BVS $6.09
  • P/E Ratio
  • PRAX N/A
  • BVS N/A
  • Revenue Growth
  • PRAX 249.53
  • BVS 11.89
  • 52 Week Low
  • PRAX $26.70
  • BVS $3.90
  • 52 Week High
  • PRAX $91.83
  • BVS $14.38
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 43.73
  • BVS 37.22
  • Support Level
  • PRAX $28.79
  • BVS $7.56
  • Resistance Level
  • PRAX $30.88
  • BVS $8.66
  • Average True Range (ATR)
  • PRAX 3.07
  • BVS 0.61
  • MACD
  • PRAX 0.88
  • BVS -0.05
  • Stochastic Oscillator
  • PRAX 56.05
  • BVS 28.40

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Share on Social Networks: